Payer Analytics Director

A second psychedelics renaissance emerges. The trajectory of the psychedelic medicine industry has never been a straight line. Like many transformative leaps in biotechnology, it has been defined by bursts of euphoric potential followed by sobering regulatory hurdles. Most notably, the sector faced a significant cooling period following the Food and Drug Administration's 2024 decision denying approval for Lykos Therapeutics' MDMA-assisted therapy, a moment that many feared would stall the movement for years. However, recent developments suggest the industry has not just survived the setback; it is maturing. According to Law360 and recent biotech market analyses, Feldman Legal Advisors is witnessing a steady surge of positive clinical data, a renewed appetite from institutional investors, and a surprising bipartisan legislative shift. While early setbacks served as a lesson in trial design, the industry's larger players now appear to be hitting their stride. As reported by Psychedelic Alpha, Compass Pathways recently announced a second positive Phase 3 trial testing its proprietary synthetic psilocybin formulation for treatment resistant depression. The company is preparing for a rolling FDA submission later this year. MindMed also has begun Phase 3 trials testing LSD-based therapy to treat generalized anxiety disorder, and Cybin is in Phase 3 testing psilocybin as a potential treatment for major depressive disorder. Cybin, along with companies such as Atai Life Sciences, is raising capital and consolidating resources to complete these final stages of their new drug trials. Perhaps the most compelling trend for legal analysts is the unique political coalition forming around these substances. A New York Times report last year, for example, highlighted former Republican Texas Governor Rick Perry's unexpected role as a vocal advocate for ibogaine research, leading to the state action outlined below. This framing has led to a remarkable phenomenon: psychedelic research appears to have robust bipartisan support, even in red states. Public opinion is mirroring this shift. 2025 polling from the UC Berkeley Center for the Science of Psychedelics shows that support for regulated therapeutic access has climbed to 72% among U.S. voters. UC Berkeley also reported that proximity to psychedelic use (knowing someone who has used them) rose significantly among conservatives, from 43% to 50% in just two years. While the federal government remains generally cautious, states are stepping up as the primary laboratories for policy reform and actual therapeutic access. In Oregon and Colorado, regulated state-legal psilocybin services are no longer theoretical, they are operational, and real patients are already gaining access through licensed programs. At the same time, the rollout has been slower and more uneven than many advocates initially hoped. High costs, licensing bottlenecks, limited facilitator supply, and the complexity of building a new regulated care model have all contributed to a gradual pace. Even so, Oregon and Colorado are now serving as an important blueprint for other states seeking to expand access more effectively. Beyond the Western states implementing state legal access programs, in 2025 Texas Gov. Greg Abbott (R) signed into law a bill establishing a state-backed research consortium to conduct clinical trials on ibogaine as a potential treatment for substance use disorders and other mental health conditions. This research will be supported by up to $50 million in state funds to be matched by private contributions. Arizona followed suit in late June 2025, when its 2026 state budget included a $5 million appropriation for a certified clinical research study on ibogaine for neurological conditions including traumatic brain injury and post-traumatic stress disorder, contingent on at least $5 million in matching non-state funds. More recently, on March 25, 2026, a Louisiana Senate committee advanced S.B. 43, which proposes using opioid settlement funds to establish clinical trials for ibogaine and psilocybin at state medical schools. The trend of state-level research initiatives further reached the Deep South this month. Mississippi Governor Tate Reeves (R) signed HB 314 into law, establishing a state-backed consortium to conduct clinical trials on ibogaine. The program's primary objective is to generate the data necessary to assist in seeking federal FDA approval for the substance as a novel treatment option. Meanwhile, over 30 states, including Massachusetts and New Jersey, are currently considering bills ranging from decriminalization to medical pilot programs. New York isconsidering multiple bills, including one that would legalize adult use of psilocybin. In addition, in 2024 Maryland established a task force to design a program that provides broad, equitable, and affordable access to natural psychedelics. The task force later recommended a multi-pathway access structure designed to allow different kinds of lawful access under one umbrella, with an initial focus on psilocybin. The Pacific is also joining this legislative wave. On March 10, 2026, the Hawaii Senate passed SB 3199, which establishes a Mental Health Emerging Therapies Task Forceto prepare for federal approval of psychedelic therapies. If enacted, the task force would be charged with a two-year mission to review scientific literature and develop clinical research. The goal would be to provide the state with recommendations for creating safe and ethical access pathways to breakthrough therapies like psilocybin and MDMA. The setbacks of the past few years, including the Lykos controversy, were not the end of the movement; rather, they may well have been its coming of age. As advocates and operators look toward the balance of the 2026 horizon, the question appears no longer to be if psychedelics will be further legalized for therapy, but how the regulatory framework will be managed to ensure safety and equity. This article was written by Magnolia Mullen, Courtney Barnes, and David Feldman. This article is for informational purposes only and is not intended to be relied upon as legal advice.